Table 6.
Bw4Ile80 | Bw4Ile80;Thr80 | Bw4Thr80 | |
---|---|---|---|
Patients | 17 (70.8%) | 1 (4.2%) | 6 (25.0%) |
Primary MM | 7 (29.2%) | 1 (4.2%) | 5 (20.8%) |
Metastatic MM | 10 (41.6%) | 0 | 1 (4.2%) |
Controls | 26 (78.8%) | 2 (6.0%) | 5 (15.2%) |
Bw4Ile80 | Bw4Ile80;Thr80 | Bw4Thr80 | |
---|---|---|---|
Patients | 17 (70.8%) | 1 (4.2%) | 6 (25.0%) |
Primary MM | 7 (29.2%) | 1 (4.2%) | 5 (20.8%) |
Metastatic MM | 10 (41.6%) | 0 | 1 (4.2%) |
Controls | 26 (78.8%) | 2 (6.0%) | 5 (15.2%) |